HotSpot Therapeutics Unveils New Phase 1 Data for HST-1011
HotSpot Therapeutics, Inc., a pioneering biotechnology company, is making strides in developing oral therapies that target regulatory sites on proteins. The company will present important Phase 1 clinical biomarker data for its investigational drug HST-1011 at a prestigious annual meeting.
About HST-1011: A Novel CBL-B Inhibitor
HST-1011 is a selective inhibitor of the Casitas B-lineage lymphoma proto-oncogene (CBL-B), which plays a crucial role in regulating immune responses. The data presented will highlight potential clinical biomarkers that may correlate with signs of activity in patients undergoing treatment. This research stems from an ongoing Phase 1 dose-escalation study, aiming to understand how the drug affects patients positively.
Presentation Details
Details for the poster presentation are as follows:
Title: Peripheral Blood and Tumor Gene Expression as Biomarkers and Potential Predictors of Clinical Outcome with HST-1011, an Oral CBL-B Inhibitor
Session Date and Time: Sat., Nov. 9, 2024, 9:00 AM-8:30 PM CT
Location: Exhibit Halls A & B, George R. Brown Convention Center
Abstract Number: 1310
Innovative Approach to Drug Development
HotSpot Therapeutics employs a unique strategy to drug discovery through its Smart Allostery™ platform. This platform integrates computational methodologies and advanced data mining techniques using AI to identify and design targeted small molecules. By focusing on natural hotspots on proteins, the company is paving the way for new therapeutic options for both cancer and autoimmune diseases.
Pipeline of Allosteric Therapies
With their innovative approach, HotSpot Therapeutics is building an extensive pipeline of allosteric therapies ready to tackle various medical conditions. The integration of bespoke chemistry and tailored pharmacology enhances their ability to discover potent and selective drugs. Their strategy is vital for the rapid advancement from discovery to clinical evaluation.
About HotSpot Therapeutics, Inc.
HotSpot Therapeutics is at the forefront of clinical-stage biotechnology, focussed on discovering a new class of allosteric drugs. The company’s commitment to systematic, thorough research and development underscores their vision of transforming patient care through effective treatments that harness natural protein dynamics.
Through innovative drug development techniques, HotSpot is determined to improve outcomes for individuals facing various health challenges. Their ongoing studies are a testament to their commitment to advancing medical science.
Frequently Asked Questions
What is HST-1011?
HST-1011 is an investigational drug developed by HotSpot Therapeutics that selectively inhibits the CBL-B protein, contributing to immune regulation.
When will the presentation take place?
The poster presentation will occur on November 9, 2024, during the Society for Immunotherapy of Cancer Annual Meeting.
What is the importance of Phase 1 data?
Phase 1 data helps to establish safety, tolerability, and preliminary effectiveness of the drug in a clinical setting, which is crucial for further study.
How does HotSpot Therapeutics discover new drugs?
The company uses its Smart Allostery™ platform, which combines AI-driven data mining and computational approaches to identify and design drugs targeting natural protein hotspots.
What diseases does HotSpot target?
HotSpot Therapeutics focuses on developing treatments for cancer and autoimmune diseases, aiming to address significant unmet medical needs.
